Loading…
Data as of .
| Company | Industry | Market cap | 1M | 6M | Revenue growth | Op. margin | Fwd P/E |
|---|---|---|---|---|---|---|---|
| Novo Nordisk A/S NOVO-B.CO | Pharmaceuticals: Major | $177B | +4% | -6% | +6% | 48% | 11.8× |
| Genmab A/S GMAB.CO | Biotechnology | $30.8B | +34% | +103% | +15% | 31% | 40.9× |
| Coloplast A/S COLO-B.CO | Medical Specialties | $16.6B | +6% | +24% | +4% | 25% | 20.0× |
| Demant A/S DEMANT.CO | Medical Specialties | $10.4B | -5% | +39% | +10% | 18% | 23.2× |
| H. Lundbeck A/S HLUN-A.CO | Pharmaceuticals: Major | $9.16B | +31% | +69% | +9% | 26% | n/a |
| ALK-abello A/S ALK-B.CO | Pharmaceuticals: Major | $7.94B | +2% | -8% | +16% | 26% | 34.8× |
| Ambu A/S AMBU-B.CO | Medical Specialties | $3.47B | +16% | +31% | +7% | 13% | 28.8× |
| Bavarian Nordic A/S BAVA.CO | Biotechnology | $2.82B | 0% | +23% | -8% | 18% | 16.6× |
| Zealand Pharma A/S ZEAL.CO | Biotechnology | $2.16B | -4% | -30% | -50% | 46% | 7.2× |
| ChemoMetec A/S CHEMM.CO | Medical Specialties | $1.77B | +21% | +107% | +3% | 49% | 46.7× |
| Embla Medical hf EMBLA.CO | Medical Specialties | $1.72B | +5% | +1% | +6% | 14% | 17.2× |